A ten-year single-center study reports 94 percent primary efficacy and 100 percent cancer-specific survival at five years for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results